MedTrace Logo

Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy

NCT02312037 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2019-08-20

No results posted yet for this study

Summary

An expanded access/compassionate use protocol that allows access to Mylotarg for relapsed/refractory AML CD33 positive patients in the USA.

Contact: [email protected]

Conditions

  • CD33 Positive Acute Myelogenous Leukemia

Interventions

BIOLOGICAL

Antibody Drug Conjugate Chemotherapeutic

Three Treatment Regimens: 1. Mylotarg \<=9 mg/m2 as a single agent on Day 1 \& 14 of a 28-day cycle for a total of two cycles 2. Mylotarg in combination with a recognized anthracycline and/or nucleoside-antagonist containing regimen 3. Mylotarg as monotherapy or in tested combinations with ATRA and/or arsenic trioxide for APL

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
3 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02312037 on ClinicalTrials.gov